KPV (5 mg) Research Peptide – Overview
The KPV (5 mg) Research Peptide is a synthetic tripeptide fragment (Lys‑Pro‑Val) derived from the human α‑melanocyte‑stimulating hormone (α‑MSH). It retains potent anti‑inflammatory, antimicrobial and wound‑healing activity while being highly stable in lyophilized form. GMP‑certified, ≥ 99 % pure (HPLC) and endotoxin‑free, it is the go‑to reagent for skin‑repair, neuro‑protective and immune‑modulation studies.
The high purity of the KPV (5 mg) Research Peptide ensures reproducible results across in‑vitro and in‑vivo models.
Key Benefits
- Powerful anti‑inflammatory action – suppresses TNF‑α, IL‑1β and IL‑6 release.
- Accelerates skin‑healing – promotes keratinocyte migration and collagen synthesis.
- Neuro‑protective properties – reduces oxidative stress in neuronal cultures.
Technical Specifications
| Specification |
Detail |
| Peptide |
KPV – 5 mg per amber vial |
| Purity |
≥ 99 % (HPLC) |
| Form |
Lyophilized powder, amber glass vial (1 mL reconstitution volume) |
| Storage |
–20 °C, desiccated; protect from light & moisture |
| Shelf‑life |
24 months when stored as recommended |
| SKU |
PL‑KPV‑5‑MG |
| GTIN / UPC |
019876543237 |
| Manufacturer |
PrymaLab |
Reconstitution & Recommended Use
- Reconstitute the vial with **1 mL sterile bacteriostatic water** → final concentration **5 mg / mL** (5 000 µg / mL). This yields a ready‑to‑use solution of the KPV 5 mg Research Peptide.
- In‑vitro dose: **10‑100 µg/mL** for anti‑inflammatory assays; **50‑200 µg/mL** for skin‑healing assays.
- In‑vivo rodent dose: **0.1‑0.5 mg/kg** sub‑cutaneously or intraperitoneally, once daily.
- Maximum single dose: **5 mg** per animal per day.
Safety Disclaimer
This product is supplied for **personal, non‑clinical research use only**. It is **not a medication** and does **not** diagnose, treat, cure or prevent any disease. Pregnant or nursing individuals, people with known medical conditions, or anyone taking prescription medication should consult a qualified health professional before use. Keep out of reach of children.